Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조수경 | - |
dc.date.accessioned | 2019-12-02T05:42:20Z | - |
dc.date.available | 2019-12-02T05:42:20Z | - |
dc.date.issued | 2017-11 | - |
dc.identifier.citation | 대한류마티스학회지, v. 24, no. 5, page. 293-302 | en_US |
dc.identifier.issn | 2093-940X | - |
dc.identifier.issn | 2233-4718 | - |
dc.identifier.uri | https://synapse.koreamed.org/DOIx.php?id=10.4078/jrd.2017.24.5.293 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/116331 | - |
dc.description.abstract | Objective. To estimate the cardiovascular (CV) and gastrointestinal (GI) risks of etoricoxib in the treatment of osteoarthritis (OA) compared to a placebo and other non-steroidal anti-inflammatory drugs (NSAIDs). Methods. A systematic review of randomized, controlled trials (RCTs) of etoricoxib were performed. Bayesian network meta-analysis was used over a duration of 12 weeks. The incidence of CV and GI events for a duration ≥26 weeks were also tabulated and presented using descriptive statistics. Results. From this search, 10 studies were identified. Of these, 6 and 5 RCTs that measured the CV and GI events at 12 weeks were included in meta-analysis. They showed that etoricoxib did not increase the CV events compared to the placebo or NSAIDs during the 12 week period (odds ratio [OR]=0.59 compared to celecoxib, OR=0.89 with ibuprofen, OR=0.70 with placebo, and OR=2.16 with naproxen). The risk of GI events was comparable to that of most comparators, with the exception of naproxen, which had a significantly lower risk of GI events (OR=0.18) during the 12 week period. For a duration ≥26 weeks, the incidence of CV and GI events with etoricoxib increased with increasing duration. Conclusion. Etoricoxib is an alternative short-term treatment option for OA, showing comparable CV and GI complications to other NSAIDs. Nevertheless, further studies will be needed to elucidate the long-term safety of etoricoxib in the treatment of OA. | en_US |
dc.description.sponsorship | This research was supported by a grant of the KoreaHealth Technology R&D Project through the KoreaHealth Industry Development Institute (KHIDI), fundedby the Ministry of Health & Welfare, Republic of Korea(grant number: HC15C3388). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | 대한류마티스학회 | en_US |
dc.subject | Anti-inflammatory agents | en_US |
dc.subject | non-steroidal | en_US |
dc.subject | Etoricoxib | en_US |
dc.subject | Osteoarthritis | en_US |
dc.subject | Safety | en_US |
dc.title | Cardiovascular and Gastrointestinal Effects of Etoricoxib in the Treatment of Osteoarthritis: A Systematic Review and Network Meta-analysis | en_US |
dc.type | Article | en_US |
dc.relation.no | 5 | - |
dc.relation.volume | 24 | - |
dc.identifier.doi | 10.4078/jrd.2017.24.5.293 | - |
dc.relation.page | 293-302 | - |
dc.relation.journal | 대한류마티스학회지 | - |
dc.contributor.googleauthor | Kim, Dam | - |
dc.contributor.googleauthor | Cho, Soo-Kyung | - |
dc.contributor.googleauthor | Nam, Seoung Wan | - |
dc.contributor.googleauthor | Kwon, Hyuk Hee | - |
dc.contributor.googleauthor | Jung, Sun-Young | - |
dc.contributor.googleauthor | Jeon, Chan Hong | - |
dc.contributor.googleauthor | Im, Seul Gi | - |
dc.contributor.googleauthor | Kim, Dalho | - |
dc.contributor.googleauthor | Jang, Eun Jin | - |
dc.contributor.googleauthor | Sung, Yoon-Kyoung | - |
dc.relation.code | 2017019219 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | skchomd | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.